IR@PKUHSC  > 北京大学第二临床医学院
学科主题临床医学
Safety of infliximab therapy in rheumatoid arthritis patients with previous exposure to hepatitis B virus
Zhang, Xuewu1; Zhang, Fengchun2; Wu, Donghai3; Bao, Chunde4; Zhu, Ping5; Zhang, Xiao6; Huang, Cibo7; He, DongYi8; Tao, Yi9; Fang, Yongfei10; Gu, Jieruo11; Wu, Huaxiang12; Sun, Lingyun13; Yang, Xiuyan14; Huang, Feng15; Xu, Huji16; Zhao, Dongbao17; Zhang, Miaojia18; Zheng, Yi19; Li, Zhanguo1
关键词HBV infection infliximab rheumatoid arthritis
刊名INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES
2013-08-01
DOI10.1111/1756-185X.12125
16期:4页:408-412
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Rheumatology
研究领域[WOS]Rheumatology
关键词[WOS]ALPHA THERAPY ; PROPHYLAXIS ; INFECTIONS ; GUIDELINES ; EFFICACY ; DRUGS
英文摘要

Objective: To evaluate the safety of tumor necrosis factor-alpha (TNF-alpha) monoclonal antibody (infliximab) therapy in patients with rheumatoid arthritis (RA) and previous exposure to hepatitis B virus (HBV) who had normal liver function.

Methods: This is a retrospective study from a 26-week, prospective, multicenter trial in 234 patients with RA who received infusions of infliximab (3 mg/kg at week 0, 2, 6, 14 and 22). The medical records of these patients were reviewed, including the information on disease duration, laboratory tests and HBV markers. The data on liver function during the study was analyzed, as well as comparison between patients with previous exposure to HBV and patients without such exposure.

Results: Forty-one patients with previous exposure to HBV were HBsAg(-). Forty patients had normal alanine aminotransferase (ALT) and aspartate aminotransferase (AST) and only one patient with positive anti-HBc showed an elevated ALT level before administration of infliximab, and had a further increase of ALT level at week 14, but decreased thereafter. The average ALT and AST levels rose slightly during the treatment but remained in normal range and the differences were insignificant compared with baseline. There was no statistically significant difference in the incidence of liver function abnormalities during the treatment of infliximab between the patients with previous exposure to HBV and those without such exposure.

Conclusion: In patients with RA and previous exposure to HBV but with a negative HBsAg and normal liver function at baseline, liver function abnormalities were not observed during infliximab treatment.

语种英语
WOS记录号WOS:000323721600008
引用统计
被引频次:3[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/61374
专题北京大学第二临床医学院
作者单位1.Beijing Hosp, Dept Rheumatol & Immunol, Beijing, Peoples R China
2.Peking Univ, Dept Rheumatol & Immunol, Peoples Hosp, Beijing 100044, Peoples R China
3.Beijing Union Med Coll Hosp, Dept Rheumatol & Immunol, Beijing, Peoples R China
4.China Japan Friendship Hosp, Dept Rheumatol & Immunol, Beijing, Peoples R China
5.Shanghai Jiao Tong Univ, Renji Hosp, Dept Rheumatol & Immunol, Shanghai 200030, Peoples R China
6.Fourth Mil Med Univ, Xijing Hosp, Dept Rheumatol & Immunol, Xian 710032, Peoples R China
7.Guangdong Prov Peoples Hosp, Dept Rheumatol & Immunol, Guangzhou, Guangdong, Peoples R China
8.Shanghai Guanghua Hosp, Dept Rheumatol & Immunol, Shanghai, Peoples R China
9.Guangzhou Med Univ, Affiliated Hosp 2, Dept Rheumatol & Immunol, Guangzhou, Guangdong, Peoples R China
10.Third Mil Med Univ, Xinan Affiliated Hosp, Dept Rheumatol & Immunol, Chongqing, Peoples R China
11.Sun Yat Sen Univ, Affiliated Hosp 3, Dept Rheumatol & Immunol, Guangzhou 510275, Guangdong, Peoples R China
12.Zhejiang Univ, Affiliated Hosp 2, Dept Rheumatol & Immunol, Hangzhou 310003, Zhejiang, Peoples R China
13.Nanjing Univ, Sch Med, Nanjing Drum Tower Hosp, Dept Rheumatol & Immunol,Affiliated Hosp, Nanjing 210008, Jiangsu, Peoples R China
14.Sun Yat Sen Univ, Affiliated Hosp 1, Dept Rheumatol & Immunol, Guangzhou 510275, Guangdong, Peoples R China
15.Chinese Peoples Liberat Army Gen Hosp, Dept Rheumatol & Immunol, Beijing, Peoples R China
16.Second Mil Med Univ, Dept Rheumatol & Immunol, Shanghai, Peoples R China
17.Second Mil Med Univ, Changhai Hosp, Dept Rheumatol & Immunol, Shanghai, Peoples R China
18.Jiangsu Prov People Hosp, Dept Rheumatol & Immunol, Nanjing, Jiangsu, Peoples R China
19.Capital Univ Med Sci, Beijing Chaoyang Affiliated Hosp, Dept Rheumatol & Immunol, Beijing, Peoples R China
推荐引用方式
GB/T 7714
Zhang, Xuewu,Zhang, Fengchun,Wu, Donghai,et al. Safety of infliximab therapy in rheumatoid arthritis patients with previous exposure to hepatitis B virus[J]. INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES,2013,16(4):408-412.
APA Zhang, Xuewu.,Zhang, Fengchun.,Wu, Donghai.,Bao, Chunde.,Zhu, Ping.,...&Li, Zhanguo.(2013).Safety of infliximab therapy in rheumatoid arthritis patients with previous exposure to hepatitis B virus.INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES,16(4),408-412.
MLA Zhang, Xuewu,et al."Safety of infliximab therapy in rheumatoid arthritis patients with previous exposure to hepatitis B virus".INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES 16.4(2013):408-412.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Zhang, Xuewu]的文章
[Zhang, Fengchun]的文章
[Wu, Donghai]的文章
百度学术
百度学术中相似的文章
[Zhang, Xuewu]的文章
[Zhang, Fengchun]的文章
[Wu, Donghai]的文章
必应学术
必应学术中相似的文章
[Zhang, Xuewu]的文章
[Zhang, Fengchun]的文章
[Wu, Donghai]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。